A phase II study of S-1 in combination with sorafenib in metastatic renal cell carcinoma

被引：0
|
作者：
Sakai, Hideki
Ohba, Kojiro
Hashine, Katsuyoshi
Tomita, Yoshihiko
Shinohara, Nobuo
Fujisawa, Masato
Eto, Masatoshi
Ozono, Seiichiro
Tsukamoto, Taiji
Akaza, Hideyuki
Naito, Seiji
机构：
[1] Nagasaki Univ, Dpartment Nephrourol, Grad Sch Biomed Sci, Nagasaki 852, Japan
[2] Natl Hosp Org Shikoku Canc Ctr, Dept Urol, Matsuyama, Ehime, Japan
[3] Yamagata Univ, Sch Med, Dept Urol, Yamagata 99023, Japan
[4] Hokkaido Univ, Dept Urol, Grad Scohool Med, Sapporo, Hokkaido, Japan
[5] Kobe Univ, Dept Urol, Grad Sch Med, Kobe, Hyogo 657, Japan
[6] Kumamoto Univ, Dept Urol, Fac Life Sci, Kumamoto, Japan
[7] Hamamatsu Univ Sch Med, Dept Urol, Hamamatsu, Shizuoka 4313192, Japan
[8] Sapporo Med Univ, Dept Urol, Sch Med, Sapporo, Hokkaido, Japan
[9] Univ Tokyo, Res Ctr Adv Sci & Technol, Tokyo, Japan
[10] Kyushu Univ, Dept Urol, Grad Sch Med Sci, Fukuoka 812, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 04期
关键词：
D O I：
10.1200/jco.2014.32.4_suppl.529
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
529
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase II Study of Sorafenib and Bortezomib for First-Line Treatment of Metastatic or Unresectable Renal Cell Carcinoma
    Rao, Arpit
    Lauer, Richard
    ONCOLOGIST, 2015, 20 (04): : 370 - 371
  • [22] Phase II Study of Pyrazoloacridine in Metastatic Renal Cell Carcinoma
    J. Philip Kuebler
    Gerald W. King
    Pierre Triozzi
    Timothy Moore
    Eric H. Kraut
    Investigational New Drugs, 2001, 19 : 327 - 328
  • [23] Phase II study of pyrazoloacridine in metastatic renal cell carcinoma
    Kuebler, JP
    King, GW
    Triozzi, P
    Moore, T
    Kraut, EH
    INVESTIGATIONAL NEW DRUGS, 2001, 19 (04) : 327 - 328
  • [24] A phase I clinical trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma
    Yi, J.
    Ahn, H.
    Lee, S.
    Uhm, J.
    Lee, J.
    Park, S.
    Park, J.
    Park, Y.
    Lim, H.
    Kang, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [25] A PHASE II STUDY OF S-1 COMBINED WITH IRINOTECAN AND OXALIPLATIN IN PATIENTS WITH METASTATIC GASTRIC CARCINOMA
    Park, S. R.
    Park, Y.
    Park, Y. L.
    Kim, N. K.
    ANNALS OF ONCOLOGY, 2008, 19 : 173 - 173
  • [26] A PHASE II STUDY OF S-1 IN PATIENTS (PTS) WITH CYTOKINE-REFRACTORY METASTATIC RENAL CELL CANCER (MRCC)
    Naito, S.
    Akaza, H.
    Usami, M.
    Tsukamoto, T.
    Shinohara, N.
    Tomita, Y.
    Namiki, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 190 - 190
  • [27] A Phase II trial of dosage escalation of sorafenib in Asian patients with metastatic renal cell carcinoma
    Wang, Hong-kai
    Zhang, Hai-liang
    Zhu, Yao
    Yao, Xu-dong
    Zhang, Shi-lin
    Dai, Bo
    Shen, Yi-jun
    Zhu, Yi-ping
    Shi, Guo-hai
    Qin, Xiao-jian
    Ma, Chun-guang
    Lin, Guo-wen
    Xiao, Wen-jun
    Ye, Ding-wei
    FUTURE ONCOLOGY, 2014, 10 (12) : 1941 - 1951
  • [28] A phase II study of combination chemotherapy with S-1 and nedaplatin as neoadjuvant manner for oral squamous cell carcinoma patients
    Nakazawa, M.
    Niki, A.
    Ogawa, F.
    Matsumoto, Y.
    Iwai, S.
    Kato, I.
    Sumi, T.
    Ohnishi, T.
    Amino, K.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S767 - S767
  • [29] Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer
    Kim, Hyeong Su
    Kim, Ho Young
    Zang, Dae Young
    Oh, Ho Suk
    Jeon, Jang Yong
    Cho, Ji Woong
    Park, Choong Kee
    Kim, Jong Hyeok
    Kim, Min-Jeong
    Ha, Hong Il
    Kim, Jung Han
    Han, Boram
    Song, Hunho
    Kwon, Jung Hye
    Choi, Dae Ro
    Jung, Joo Young
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (04) : 711 - 718
  • [30] Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer
    Hyeong Su Kim
    Ho Young Kim
    Dae Young Zang
    Ho Suk Oh
    Jang Yong Jeon
    Ji Woong Cho
    Choong Kee Park
    Jong Hyeok Kim
    Min-Jeong Kim
    Hong Il Ha
    Jung Han Kim
    Boram Han
    Hunho Song
    Jung Hye Kwon
    Dae Ro Choi
    Joo Young Jung
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 711 - 718
12345